Phase II open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma

BACKGROUND: Despite the recent development of new therapies, multiple myeloma (MM) remains an incurable disease. Thus, new, effective treatments are urgently needed, particularly for relapsed or refractory MM (RRMM). In an earlier phase I study, a novel form of recombinant human Apo2L/tumor necrosis...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Chin J Cancer
Main Authors: Leng, Yun, Qiu, Lugui, Hou, Jian, Zhao, Yaozhong, Zhang, Xuejun, Yang, Shifang, Xi, Hao, Huang, Zhongxia, Pan, Ling, Chen, Wenming
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2016
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5016961/
https://ncbi.nlm.nih.gov/pubmed/27608772
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40880-016-0140-0
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados